Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.
Identifieur interne : 000119 ( PubMed/Corpus ); précédent : 000118; suivant : 000120Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.
Auteurs : Mingxiang Ye ; Dian Fu ; Yi Ren ; Faxiang Wang ; Dong Wang ; Fang Zhang ; Xinyi Xia ; Tangfeng LvSource :
- Journal of medical virology [ 1096-9071 ] ; 2020.
Abstract
The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergency. A handful of literatures have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. In order to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground glass opacities (GGOs) and consolidation in patient #1, #2, #3, #4 and #6. In patient #1 and #5 who presented with SARS-CoV-2 in throat swab, convalescent plasma therapy elicited an elimination of virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patient #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-art therapy during COVID-19 pandemic crisis. This article is protected by copyright. All rights reserved.
DOI: 10.1002/jmv.25882
PubMed: 32293713
Links to Exploration step
pubmed:32293713Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.</title><author><name sortKey="Ye, Mingxiang" sort="Ye, Mingxiang" uniqKey="Ye M" first="Mingxiang" last="Ye">Mingxiang Ye</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Fu, Dian" sort="Fu, Dian" uniqKey="Fu D" first="Dian" last="Fu">Dian Fu</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Ren, Yi" sort="Ren, Yi" uniqKey="Ren Y" first="Yi" last="Ren">Yi Ren</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Faxiang" sort="Wang, Faxiang" uniqKey="Wang F" first="Faxiang" last="Wang">Faxiang Wang</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Dong" sort="Wang, Dong" uniqKey="Wang D" first="Dong" last="Wang">Dong Wang</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Fang" sort="Zhang, Fang" uniqKey="Zhang F" first="Fang" last="Zhang">Fang Zhang</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xia, Xinyi" sort="Xia, Xinyi" uniqKey="Xia X" first="Xinyi" last="Xia">Xinyi Xia</name><affiliation><nlm:affiliation>Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lv, Tangfeng" sort="Lv, Tangfeng" uniqKey="Lv T" first="Tangfeng" last="Lv">Tangfeng Lv</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32293713</idno><idno type="pmid">32293713</idno><idno type="doi">10.1002/jmv.25882</idno><idno type="wicri:Area/PubMed/Corpus">000119</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000119</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.</title><author><name sortKey="Ye, Mingxiang" sort="Ye, Mingxiang" uniqKey="Ye M" first="Mingxiang" last="Ye">Mingxiang Ye</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Fu, Dian" sort="Fu, Dian" uniqKey="Fu D" first="Dian" last="Fu">Dian Fu</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Ren, Yi" sort="Ren, Yi" uniqKey="Ren Y" first="Yi" last="Ren">Yi Ren</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Faxiang" sort="Wang, Faxiang" uniqKey="Wang F" first="Faxiang" last="Wang">Faxiang Wang</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Dong" sort="Wang, Dong" uniqKey="Wang D" first="Dong" last="Wang">Dong Wang</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Fang" sort="Zhang, Fang" uniqKey="Zhang F" first="Fang" last="Zhang">Fang Zhang</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xia, Xinyi" sort="Xia, Xinyi" uniqKey="Xia X" first="Xinyi" last="Xia">Xinyi Xia</name><affiliation><nlm:affiliation>Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lv, Tangfeng" sort="Lv, Tangfeng" uniqKey="Lv T" first="Tangfeng" last="Lv">Tangfeng Lv</name><affiliation><nlm:affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergency. A handful of literatures have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. In order to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground glass opacities (GGOs) and consolidation in patient #1, #2, #3, #4 and #6. In patient #1 and #5 who presented with SARS-CoV-2 in throat swab, convalescent plasma therapy elicited an elimination of virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patient #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-art therapy during COVID-19 pandemic crisis. This article is protected by copyright. All rights reserved.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32293713</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.25882</ELocationID><Abstract><AbstractText>The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergency. A handful of literatures have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. In order to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground glass opacities (GGOs) and consolidation in patient #1, #2, #3, #4 and #6. In patient #1 and #5 who presented with SARS-CoV-2 in throat swab, convalescent plasma therapy elicited an elimination of virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patient #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-art therapy during COVID-19 pandemic crisis. This article is protected by copyright. All rights reserved.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Mingxiang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Dian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Faxiang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency, 904 Hospital, Wuxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Xinyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Wuhan Huoshenshan Hospital, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Tangfeng</ForeName><Initials>T</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7224-8468</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease, Unit 4-1, Wuhan Huoshenshan Hospital, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">convalescent plasma therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32293713</ArticleId><ArticleId IdType="doi">10.1002/jmv.25882</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32293713
|texte= Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32293713" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |